Garth Lees-Rolfe - Chief Financial Officer at Inhibikase Therapeutics, Inc.

Issuer-level insider activity

Role
Chief Financial Officer
Issuer ticker
IKT on Nasdaq
Identity Names, identifiers, and filing context for this profile. 1 identity field
Entity type
Individual
Source evidence Original filing metadata and source links for verification. 1 source field
Source filing history
Open source filing history

No buys or sells have been reported by Garth Lees-Rolfe since 26 Jul 2025

Reported holdings for Garth Lees-Rolfe in Inhibikase Therapeutics, Inc.

Form 4 holding Chief Financial Officer

Inhibikase Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
90,000
Estimated value
Report date
21 Jan 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Transaction history for Garth Lees-Rolfe in Inhibikase Therapeutics, Inc.

Sym Class Transaction % SEC-reported value SEC-reported price Shares Shares after Date Ownership
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .